JILLIAN LAMARCA: Open Payments
NPI 1891928750 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,713 in 97 payments from 20 companies in 2025. Trend: 2023 $1,700 · 2024 $1,502 · 2025 $1,713
Food & beverage: $1,713
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $330 |
| PFIZER INC. | 16 | $224 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $146 |
| ABBVIE INC. | 7 | $145 |
| Lilly USA, LLC | 9 | $132 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $122 |
| GlaxoSmithKline, LLC. | 7 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| Edwards Lifesciences Corporation | 3 | $80 |
| Abbott Laboratories | 2 | $44 |
Products named: Wegovy, JARDIANCE, XIFAXAN, MOUNJARO, CAPLYTA, NURTEC ODT, UBRELVY, Ozempic.
Industry payments across NY — which companies pay providers there.
